OncoMed

Celgene ditches option to license OncoMed’s navicixizumab

Celgene is walking away from navicixizumab, a bispecific antibody that became OncoMed’s lead asset after midstage failures scuppered a couple of other candidates.

Amirah Al Idrus Sep 20, 2018 3:56pm

woman with back to camera working in a laboratory

A 2-pronged attack could improve colon cancer therapy

May 16, 2018 5:35pm

FierceBiotech’s rotten tomatoes and ripening fruit 2017

Mar 6, 2018 9:30am

Chutes & Ladders—Pfizer’s oncology head leaves for Novartis

Jan 12, 2018 8:36am

With a sense of inevitability, OncoMed swings the ax on half of staffers

Apr 25, 2017 4:53am

OncoMed tanks as phase 2 cancer trial flops and Bayer flees

Apr 10, 2017 9:42am